Quintiles to Invest in Prana Biotechnology

Quintiles to Invest in Prana Biotechnology
Prana to Place up to 225 Million Shares to Clients of Southern Cross Equities to Assist in Funding Definitive Phase II Clinical Trial Into Alzheimer's Disease 

MELBOURNE, AUSTRALIA, Jun 28, 2010 (MARKETWIRE via COMTEX) -- Prana Biotechnology Limited (PRAN 1.10, 0.00, 0.00%) (ASX: PBT) today announced that it had reached an agreement with leading clinical research provider Quintiles that will see Quintiles subscribe for up to US$2 million in new Prana shares. The Company also announced that it had signed a mandate agreement with Southern Cross Equities Limited for the private placement of up to 225 million new shares to assist in the funding of Prana's planned Definitive Phase II Clinical Trial into Alzheimer's Disease.

Investment by Quintiles

Quintiles is a leading global fully integrated biopharmaceutical services company, offering commercial consulting and capital solutions worldwide. Quintiles has been intimately involved with Prana for a number of years and acted as the clinical research partner for Prana's last successful clinical trial. Quintiles has agreed to support the future activities of Prana via:


1.  The acquisition of 7,064,749 new ordinary shares in Prana at an issue
    price of AUD$0.1624 (16.24 cents per share) raising AUD1.15 million.
2.  An agreement to subscribe for up to a further US$1 million (AUD1.15m) of
    new Prana shares in the private placement being conducted by Southern
    Cross Equities.


Prana is delighted to have secured an organization of the caliber and influence of Quintiles as a significant shareholder and supporter of Prana's therapeutic goals.

Placement To Clients of South Cross Equities

Prana also announced today that it had signed a mandate with Southern Cross Equities for the placement of up to 225 million new shares at a price no less than 80% of the volume weight average price (VWAP) of Prana shares for the five days prior to the date of the placement. This placement, which is subject to shareholder approval, has been initiated to raise sufficient capital to enable the Company to conduct a definitive Phase II clinical trial of its lead Alzheimer's Disease drug PBT2.

The results of PBT2's completed Phase IIa clinical trial, previously reported in The Lancet Neurology (July 2008 and an erratum in July 2009), showed that patients with mild Alzheimer's Disease experienced an overall statistically significant improvement in Executive Function on the Neuropsychological Test Battery (NTB) within 12 weeks of treatment. Improvement in Executive Function is strongly related to improvement in daily function and to the quality of the daily life of patients.

The planned Phase II trial will involve 525 patients with mild to moderate Alzheimer's Disease. Treatment will be over a period of 12 months, with the key performance measure being cognition. Data from the Phase II trial will consolidate the evidence that PBT2 improves cognition and could go on to become the market leader in the $10 billion per annum market for Alzheimer's Disease therapeutics.

"We are delighted to have the participation of Quintiles in respect to our proposed fund raising and their support of our new Phase II trial in Alzheimer's Disease. Quintiles is a highly regarded global expert in clinical trials and therapeutics and we welcome them as a shareholder in Prana," said Geoffrey Kempler, Chairman/CEO of Prana.

Corporate

The initial placement of 7,064,749 shares at 16.24 cents per share to Quintiles has been made in accordance with Prana's 15% discretionary capacity as permitted under Chapter 7 of the Australian Securities Exchange Listing Rules. Completion of the placement with Southern Cross Equities is subject to the approval of Prana shareholders and a meeting will be convened shortly to consider this matter.

About Prana Biotechnology Limited Prana Biotechnology was established to commercialise research into Alzheimer's Disease and other major age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

For further information please visit the Company's web site at www.pranabio.com.

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.